Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 11Unknown 8Recruiting 4Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Classical hematology 1

Conditions

Venous Thromboembolism 1Multiple Myeloma 1

Interventions

Drug Therapy 107Cisplatin 97Radiotherapy 89Carboplatin 87Bevacizumab 79Oxaliplatin 74tislelizumab 68Capecitabine 68Gemcitabine 64Cyclophosphamide 64toripalimab 62Paclitaxel 57pembrolizumab 55sintilimab 53Specimen Handling 53Surgical Procedures, Operative 52anlotinib 49Fluorouracil 49Magnetic Resonance Spectroscopy 48Immune Checkpoint Inhibitors 43Blood Specimen Collection 42130-nm albumin-bound paclitaxel 42Standard of Care 38camrelizumab 36fludarabine 35lenvatinib 34Leucovorin 34venetoclax 30Radiosurgery 30Immunotherapy 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × OTHER × Rivaroxaban × Clear all
NCT06580223 2025-07-18

Aspirin or Rivaroxaban Thromboprophylaxis for Patients With Multiple Myeloma

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Phase 3 Not yet recruiting
530 enrolled
Classical hematologyPlasma cell

Multiple Myeloma, Venous Thromboembolism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡